CTOs on the Move

Metabolic Solutions Development

www.msdrx.com

 
Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised nearly $55 million in support of the development of its novel therapeutic drugs, MSDC-0160 and MSDC-0602, which selectively modulate mitochondrial control of to important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes. Such imbalances may also play a role in other diseases of aging such as Alzheimer’s disease and Parkinson’s disease, as well ...
  • Number of Employees: 5K-10K
  • Annual Revenue: $0-1 Million
  • www.msdrx.com
  • 161 E. Michigan Ave. 4th Floor
    Kalamazoo, MI USA 49007
  • Phone: 269.343.6732

Executives

Name Title Contact Details

Funding

Metabolic Solutions Development raised $16.1M on 09/25/2015

Similar Companies

Advanced Urology

Advanced Urology provides cutting-edge Vasectomy, Circumcision, InterStim, Urolift, Cytoscopy, TURP, Vasectomy Reversal & IPP. Contact us today for an initial consult.

Rénibus Therapeutics

Rénibus Therapeutics® Inc. | A biotech company dedicated to transforming the cardio-renal disease treatment paradigm by focusing on the prevention, treatment, and diagnostic testing of kidney disease.

Prescription Solutions by OptumRx

Prescription Solutions is an innovative pharmacy benefit management company managing the prescription drug benefit of commercial, Medicare and other governmental health plans, as well as those of employers and unions. A UnitedHealth Group company,

Teva Pharmaceuticals

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company headquartered in Petah Tikva, Israel.

Merck Frosst Canada

Merck Frosst Canada is a Kirkland, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.